The Super Crowd, Inc., a public benefit corporation, announced that Rejuvenate Bio and Eisana Health earned top honors at the quarterly Superpowers for Good Live Pitch, broadcast live on the e360tv Network. The event featured four innovative companies raising capital through Regulation Crowdfunding: Eisana Health, Emission Free Generators, Rejuvenate Bio and SenoGuard. Each company pitched live, answered questions from a panel of expert judges, and fielded questions from the viewing audience.
The judges selected Rejuvenate Bio, led by CEO Daniel Oliver, as the Judges' Choice Award winner. Rejuvenate Bio is developing one-time gene therapies designed to address chronic, age-related diseases, beginning with companion animals and building toward broader human longevity as the destination. “We are deeply honored to receive the Judges’ Choice Award,” said Oliver. “The Superpowers for Good Live Pitch gave us a powerful opportunity to share our vision for extending healthspan through gene therapy, as well as our traction in the animal health market. We are grateful to the judges for their thoughtful questions and to the SuperCrowd community for engaging so seriously with the science and the potential impact of our work.”
The live audience selected Eisana Health, led by CEO Carole Spangler Vaughn, as the winner of the SuperCrowd Award, the audience-choice honor. Eisana Health is developing a mobile cooling system designed to help reduce chemotherapy-induced peripheral neuropathy, a painful and often lasting side effect of cancer treatment. “We are thrilled and grateful that the audience chose Eisana Health for the SuperCrowd Award,” said Vaughn. “Our mission is personal and urgent: to help cancer patients preserve quality of life during and after treatment. It was exciting to see viewers connect with that mission, ask thoughtful questions, and recognize the need for innovation that supports patients beyond survival.”
The judging panel included Paul Lovejoy, Principal Advisor at Stakeholder Enterprise; Teddy Lyons, Senior Investment Associate at KingsCrowd; and Sherwood “Woodie” Neiss, Principal and Chief Crowdfunding Data Analyst at Crowdfund Capital Advisors, Partner at Crowd Capital Ventures, and co-founder of GUARDD, Inc. “The judges had a genuinely difficult decision,” said Devin Thorpe, CEO of The Super Crowd, Inc. and host of Superpowers for Good. “All four companies brought compelling solutions to the stage. Rejuvenate Bio impressed the judges with its ambitious science, strategic development path and potential to transform treatment for age-related disease. At the same time, the audience voting was remarkably close, and Eisana Health’s patient-centered mission clearly resonated with viewers.”
Thorpe added, “I’m proud of both winners and grateful to every founder who pitched. This event showed exactly why we created the Superpowers for Good Live Pitch: to help the public discover high-impact companies, watch serious investor-style questions unfold in real time, and participate directly by asking questions and voting.” The Superpowers for Good Live Pitch is produced by The Super Crowd, Inc. and broadcast quarterly on the e360tv Network, available via Roku, Amazon Fire TV and other connected television platforms. The program highlights companies raising capital from the crowd with potential for both financial return and social or environmental impact. For more information about Superpowers for Good and upcoming Live Pitch events, visit TheSuperCrowd.com.
This news matters because it showcases how Regulation Crowdfunding is enabling early-stage health technology companies to access capital and public visibility. The winners—Rejuvenate Bio with its gene therapy approach to age-related diseases and Eisana Health with its patient-focused solution for chemotherapy side effects—represent innovations that could significantly impact animal and human health. The event also highlights the growing trend of impact investing, where investors seek both financial returns and social good. For readers, these developments could mean future access to transformative treatments, while for the industry, they signal a shift toward democratized funding and patient-centered innovation.
